各组脑血管并发症绘制比例Meta分析[24] ■ 高剂量阿加糖酶β可中和更多的抗药抗体(ADA) 由于患者溶酶体缺乏α-Gal A活性,使用ERT时可导致ADA的形成。相同剂量下,阿加糖酶β(0.2 mg/kg/2周)和阿加糖酶α(0.2 mg/kg/2周)产生ADA的患者比例无显著差异(P=0.18)[25]。高剂量ERT可在输注过程中克服ADA滴度,更多的ERT可进入细胞溶酶体中,帮助改善患者预后[1,26-27]。Lenders等发现高剂量阿加糖酶β所致抗体饱和与较好的临床结局相关[27]。 注射过程中ERT和ADA的示意图模型[26] 注射用阿加糖酶β作为国内首个获批的法布雷病特效药,填补了国内法布雷病特异性治疗药物的空白和临床未被满足的需求,高剂量阿加糖酶β可更好的、长期稳定的保护肾/心/脑功能,改善患者生活质量及预后。 参考文献:1.中国法布雷病专家协作组. 中国法布雷病诊疗专家共识(2021年版)[J]. 中华内科杂志, 2021,60(4):321-330. DOI: 10.3760/cma.j.cn112138-20201218-01028.2. 刘吉华. 中药生物技术(第2版). 北京: 中国医药科技出版社, 2015.3. Gupta SK, Shukla P. Glycosylation control technologies for recombinant therapeutic proteins[J]. Appl Microbiol Biotechnol, 2018,102(24):10457-10468. DOI: 10.1007/s00253-018-9430-6.4. Ioannou YA, Zeidner KM, Gordon RE, et al. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice[J]. Am J Hum Genet, 2001,68(1):14-25. DOI: 10.1086/316953.5. Bishop DF, Calhoun DH, Bernstein HS, et al. Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme[J]. Proc Natl Acad Sci U S A, 1986,83(13):4859-4863. DOI: 10.1073/pnas.83.13.4859.6. 国家药品监督管理局. 注射用阿加糖酶β说明书. 核准日期2019年12月18日7. Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts[J]. Mol Genet Metab Rep, 2019,19: 100454. DOI: 10.1016/j.ymgmr.2019.100454.8. 李沅锴, 陈楠, 庄守纲. 法布里病的诊断现状及酶替代治疗进展[J]. 中华肾脏病杂志, 2017,33(2):150‑154. DOI: 10.3760/cma.j.issn.1001‑7097.2017.02.01.9. 王登, 刘煜, 等. 用于重组蛋白表达的哺乳动物细胞系的研究进展[J]. 药物生物技术, 2014,21(5):478-482. DOI: CNKI:SUN:YWSW.0.2014-05-024.10. 董文博, 陈洪栋, 郝建国, 等. 用于药用蛋白生产的外源表达系统[J]. 基因组学与应用生物学, 2009,28(4):793-802. DOI: 10.3969/gab.028.000793.11. Wurm FM, Hacker D. First CHO genome[J]. Nat Biotechnol, 2011,29(8):718-720. DOI: 10.1038/nbt.1943.12. Kim JY, Kim YG, Lee GM. CHO cells in biotechnology for production of recombinant proteins: current state and further potential[J]. Appl Microbiol Biotechnol, 2012,93(3):917-930. DOI: 10.1007/s00253-011-3758-5.13. 国家卫健委. 新冠病毒疫苗接种技术指南(第一版). 2021年3月29日. http://www.nhc.gov.cn/jkj/s3582/202103/c2febfd04fc5498f916b1be080905771.shtml, accessed in Apr.14. Ballez JS, Mols J, Burteau C, etal. Plant protein hydrolysates support CHO-320 cells proliferation and recombinant IFN-gamma production in suspension and inside microcarriers in protein-free media[J]. Cytotechnology, 2004,44(3):103-114. DOI: 10.1007/s10616-004-1099-2.15. Betanska K, Czogalla S, Spindler-Barth M, et al. Influence of cell cycle on ecdysteroid receptor in CHO-K1 cells[J]. Arch Insect Biochem Physiol, 2009,72(3):142-153. DOI: 10.1002/arch.20306.16. Amann T, Hansen AH, Kol S, et al. Glyco-engineered CHO cell lines producing alpha-1-antitrypsin and C1 esterase inhibitor with fully humanized N-glycosylation profiles[J]. Metab Eng, 2019,52:143-152. DOI: 10.1016/j.ymben.2018.11.014.17. Rasheed S, Nelson-Rees WA, Toth EM, et al. Characterization of a newly derived human sarcoma cell line (HT-1080)[J]. Cancer, 1974,33(4):1027-1033. DOI: 10.1002/1097-0142(197404)33:4<1027::aid-cncr2820330419>3.0.co;2-z.18. Jing CQ, Guo ML, Wang C, et al. Fusion with matrix attachment regions enhances expression of recombinant protein in human HT-1080 cells[J]. J Biosci Bioeng, 2020,130(5):533-538. DOI: 10.1016/j.jbiosc.2020.07.007.19. 李琴, 王天云, 王小引, 等. 用于重组药物蛋白生产的人源化细胞系研究进展[J]. 中国免疫学杂志, 2018,34(8):1274-1277,封3. DOI: 10.3969/j.issn.1000-484X.2018.08.030.20. Sirrs S, et al. Canadian Fabry disease treatment guidelines 2018. 2019‑10‑04. https://garrod.ca/wp‑content/uploads/2020/02/Canadian‑Fabry‑Treatment‑Guidelines‑2019‑final.pdf21. van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy[J]. BiochimBiophys Acta, 2011, 1812(1): 70‑76. DOI: 10.1016/j.bbadis.2010.09.007.22. Sirs SM, et al. Differential effects of agalsidase alfa and agalsidase beta in Fabry outcomes: 10 year outcomes form the Canadian Fabry Disease Initiative. CFDI Poster.23. Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study[J]. J Med Genet, 2018,55(5):351-358. DOI: 10.1136/jmedgenet-2017-104863.24. El Dib R, Gomaa H, Ortiz A, et al. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies[J]. PLoS One, 2017,12(3):e0173358. DOI: 10.1371/journal.pone.0173358.25. Rombach SM, Aerts JM, Poorthuis BJ, et al. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome[J]. PLoS One, 2012;7(10):e47805. DOI: 10.1371/journal.pone.0047805.26. Lenders M, Neußer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease[J]. J Am Soc Nephrol, 2018,29(12):2879-2889. DOI: 10.1681/ASN.2018070740.27. Lenders M, Schmitz B, Brand SM, et al. Characterization of drug‑neutralizing antibodies in patients with Fabry disease during infusion[J]. J Allergy Clin Immunol, 2018,141(6):2289-2292. DOI: 10.1016/j.jaci.2017.12.1001. MAT-CN-2107958 有效期至2023年5月 该信息仅作医学和科研参考,赛诺菲不建议以任何与您所在国家所批准的处方信息不符的方式使用本产品,本材料仅供医疗卫生专业人士使用。 来源:医学界校对:臧恒佳制版:舒茜